China has consolidated control over critical pharmaceutical supply chains, threatening American independence in medicine production and access. The country dominates the manufacturing of active pharmaceutical ingredients and finished drugs, creating vulnerabilities in U.S. healthcare security.

The Hill reports that Chinese firms leverage economic advantages to undercut American and allied manufacturers. This concentration affects everything from antibiotics to cancer treatments. Policymakers worry that geopolitical tensions could interrupt drug supplies or compromise product quality without oversight.

The U.S. faces a structural problem. After decades of cost-cutting, American manufacturers largely exited raw ingredient production. China filled that void. Today, the country supplies roughly 80 percent of active pharmaceutical ingredients to the global market. India, which relies on Chinese inputs, adds another layer of dependency.

Recent administrations have recognized the threat. The Trump and Biden administrations both pushed for "nearshoring" pharmaceutical production. This means relocating manufacturing to allied nations with similar regulatory standards and political alignment.

Proposed solutions include strengthening the FDA's inspection authority over foreign manufacturers, offering tax incentives for domestic production, and funding advanced manufacturing facilities in the U.S. Congress has considered legislation to reduce reliance on Chinese supply chains through grants and low-interest loans.

The biomedical industry presents a test case for whether America can rebuild domestic manufacturing capacity without crippling consumers with higher drug prices. Current policy debates center on balancing national security with affordable healthcare.

Rebuilding American pharmaceutical independence requires years of investment and faces resistance from companies profiting under current arrangements. Without action, China's leverage over medicine supplies grows, leaving the U.S. vulnerable during crises and dependent on a strategic competitor.